Skip to main content
. 2022 Jul 2;24(11):2090–2106. doi: 10.1007/s12094-022-02872-1

Fig. 1.

Fig. 1

Clinical risk factors and main pathogenic mechanisms of osteoporosis in patients with breast cancer and prostate cancer. ADT androgen deprivation therapy, AI aromatase inhibitors, BMD bone mineral density, BMI body mass index, GC glucocorticoids, LHRH luteinizing hormone-releasing hormone, PTHrP parathyroid hormone-related protein, RANKL/RANK receptor activator of the NF-κB (L: ligand), TGFβ transforming growth factor beta